CY1123071T1 - Μορια προσδεσης il-18 - Google Patents
Μορια προσδεσης il-18Info
- Publication number
- CY1123071T1 CY1123071T1 CY20201100582T CY201100582T CY1123071T1 CY 1123071 T1 CY1123071 T1 CY 1123071T1 CY 20201100582 T CY20201100582 T CY 20201100582T CY 201100582 T CY201100582 T CY 201100582T CY 1123071 T1 CY1123071 T1 CY 1123071T1
- Authority
- CY
- Cyprus
- Prior art keywords
- bind
- binding molecules
- complex
- inflammatory diseases
- autoimmune
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Η IL-18 συμμετέχει τόσο στην εγγενή όσο και στην επίκτητη ανοσία. Η βιοδραστικότητα της IL-18 ρυθμίζεται αρνητικά από την πρωτεΐνη πρόσδεσης IL-18 (IL18BP), έναν φυσικώς απαντώμενο και υψηλά ειδικό αναστολέα. Η διαλυτή πρωτεΐνη σχηματίζει ένα σύμπλοκο με ελεύθερη IL-18 αποτρέποντας την αλληλεπίδραση της με τον υποδοχέα IL-18, εξουδετερώνοντας και αναστέλλοντας έτσι τη βιολογική της δραστικότητα. Η παρούσα εφεύρεση αποκαλύπτει μόρια πρόσδεσης, ειδικότερα αντισώματα ή θραύσματα αυτών, τα οποία προσδένουν την IL-18 και δεν προσδένουν την IL-18 προσδεδεμένη σε IL-I8BP (σύμπλοκο IL-18/IL-18BP). Εκτός από τον φυσιολογικό της ρόλο, η IL-I8 έχει δειχθεί ότι μεσολαβεί σε μια ποικιλία από αυτοάνοσες και φλεγμονώδεις ασθένειες. Τα μόρια πρόσδεσης της εφεύρεσης μπορεί να χρησιμοποιούνται ως θεραπευτικά μόρια για τη θεραπευτική αγωγή σχετιζόμενων με την 1L-18 αυτοάνοσων και φλεγμονωδών ασθενειών ή ως διαγνωστικά εργαλεία για τον χαρακτηρισμό, την ανίχνευση ή/και μέτρηση της IL-18 που δεν προσδένεται σε IL-18BP ως συστατικό της συνολικής ομάδας IL-18.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261697981P | 2012-09-07 | 2012-09-07 | |
PCT/IB2013/058317 WO2014037899A2 (en) | 2012-09-07 | 2013-09-05 | Il-18 binding molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1123071T1 true CY1123071T1 (el) | 2021-10-29 |
Family
ID=49596347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20201100582T CY1123071T1 (el) | 2012-09-07 | 2020-06-24 | Μορια προσδεσης il-18 |
Country Status (41)
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20200308A1 (ar) * | 2012-09-07 | 2017-06-16 | Novartis Ag | جزيئات إرتباط il-18 |
WO2015032932A1 (en) * | 2013-09-05 | 2015-03-12 | Ab2 Bio Sa | Il-18 binding protein (il-18bp) in inflammatory diseases |
US10786578B2 (en) | 2014-08-05 | 2020-09-29 | Novartis Ag | CKIT antibody drug conjugates |
JP7274259B2 (ja) * | 2015-03-05 | 2023-05-16 | エイビー2 バイオ ソシエテアノニム | 炎症性疾患におけるil-18結合タンパク質(il-18bp)および抗体 |
WO2017076805A1 (en) * | 2015-11-02 | 2017-05-11 | Glaxosmithkline Intellectual Property Development Limited | Use of an inhibitor of il18 for treatment of acute kidney injury |
LT3370768T (lt) | 2015-11-03 | 2022-05-25 | Janssen Biotech, Inc. | Antikūnai, specifiškai surišantys pd-1, ir jų panaudojimas |
CN108218978B (zh) * | 2016-12-13 | 2020-05-12 | 沈阳何氏眼产业集团有限公司 | 一种重组白细胞介素18及其制备方法与应用 |
CN110382002A (zh) | 2017-03-09 | 2019-10-25 | Mab发现股份有限公司 | 特异性结合人il-1r7的抗体 |
UY37758A (es) | 2017-06-12 | 2019-01-31 | Novartis Ag | Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos |
BR112020004389A2 (pt) * | 2017-09-06 | 2020-09-08 | Yale University | composição, e, método para tratar ou prevenir uma doença ou distúrbio em um indivíduo em necessidade do mesmo. |
WO2019213686A1 (en) * | 2018-05-10 | 2019-11-14 | The Council Of The Queensland Institute Of Medical Research | Therapeutic compositions and uses therefor |
US20210317200A1 (en) | 2018-12-03 | 2021-10-14 | mAbProtein Co., Ltd. | Antibody that recognizes neoepitope of activated interleukin-18 proteins and application thereof |
CN109870570A (zh) * | 2018-12-29 | 2019-06-11 | 广东云天抗体生物科技有限公司 | 一种检测猴il-18的酶联免疫试剂盒 |
TW202233675A (zh) | 2020-10-29 | 2022-09-01 | 瑞士商諾華公司 | Il-18拮抗劑用於治療和/或預防異位性皮炎或相關病症之用途 |
WO2022221264A1 (en) * | 2021-04-12 | 2022-10-20 | Ethos Biosciences, Inc. | Methods and compositions for analysis of acute kidney injury |
TW202306989A (zh) | 2021-06-22 | 2023-02-16 | 瑞士商諾華公司 | 用於在治療化膿性汗腺炎中使用的雙特異性抗體 |
JPWO2023286694A1 (el) | 2021-07-13 | 2023-01-19 | ||
WO2023134767A1 (zh) * | 2022-01-14 | 2023-07-20 | 和径医药科技(上海)有限公司 | 一种靶向IL-18Rβ的抗体及其应用 |
WO2023178192A1 (en) | 2022-03-15 | 2023-09-21 | Compugen Ltd. | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer |
US20230357381A1 (en) * | 2022-04-26 | 2023-11-09 | Novartis Ag | Multispecific antibodies targeting il-13 and il-18 |
Family Cites Families (132)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
AU612370B2 (en) | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
JP2989002B2 (ja) | 1988-12-22 | 1999-12-13 | キリン―アムジエン・インコーポレーテツド | 化学修飾顆粒球コロニー刺激因子 |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
JPH03230220A (ja) | 1990-02-05 | 1991-10-14 | Seiko Epson Corp | ソート処理方法 |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
CA2089661C (en) | 1990-08-29 | 2007-04-03 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
US5885793A (en) | 1991-12-02 | 1999-03-23 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
CA2140280A1 (en) | 1992-08-17 | 1994-03-03 | Avi J. Ashkenazi | Bispecific immunoadhesins |
AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ES2108460T3 (es) | 1993-06-03 | 1997-12-16 | Therapeutic Antibodies Inc | Fragmentos de anticuerpos en terapeutica. |
JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
TW464656B (en) | 1994-11-15 | 2001-11-21 | Hayashibara Biochem Lab | Interferon-gamma production inducing polypeptide monoclonal antibody, and agent for interferon-gamma susceptive disease |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
JP2009047705A (ja) | 1996-07-31 | 2009-03-05 | Hayashibara Biochem Lab Inc | 生物学的試料の検出方法 |
JP2007121310A (ja) | 1996-07-31 | 2007-05-17 | Hayashibara Biochem Lab Inc | 自己免疫疾患診断剤 |
US7141393B2 (en) | 1996-12-26 | 2006-11-28 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin-18-receptor proteins |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
WO1998052976A1 (en) | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
NZ505880A (en) | 1998-01-23 | 2003-06-30 | Immunex Corp | IL-18 receptor polypeptides |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
CA2276216A1 (en) | 1998-06-24 | 1999-12-24 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | An artificial peptide capable of neutralizing the biological activity of interleukin-18 |
IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
PL209786B1 (pl) | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
AR022952A1 (es) | 1999-03-19 | 2002-09-04 | Smithkline Beecham Corp | ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL |
ES2569919T3 (es) | 1999-04-09 | 2016-05-13 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de una molécula inmunofuncional |
US6432678B1 (en) | 1999-06-21 | 2002-08-13 | Smithkline Beecham Corporation | Macaca cynomolgus IL 18 |
DE19932688B4 (de) | 1999-07-13 | 2009-10-08 | Scil Proteins Gmbh | Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen |
IL142025A0 (en) | 1999-07-20 | 2002-03-10 | Morphosys Ag | Novel methods for displaying (poly) peptides/proteins on bacteriophage particles via disulfide bonds |
CN1371416B (zh) | 1999-08-24 | 2012-10-10 | 梅达里克斯公司 | 人ctla-4抗体及其应用 |
JP3230220B2 (ja) | 1999-10-07 | 2001-11-19 | 独立行政法人 農業技術研究機構 | ブタ由来インターロイキン−18に対するモノクローナル抗体 |
DE60041432D1 (de) | 1999-11-16 | 2009-03-12 | Hayashibara Biochem Lab | Antikörper spezifisch für den Interleukin-18 Vorläufer |
PL356836A1 (en) | 2000-02-10 | 2004-07-12 | Abbott Laboratories | Antibodies that bind human interleukin-18 and methods of making and using |
CN101062415A (zh) * | 2000-02-21 | 2007-10-31 | 应用研究系统Ars股份公司 | Il-18抑制剂的应用 |
PT1278540E (pt) | 2000-05-05 | 2008-07-03 | Inst Nat Sante Rech Med | Utilização de inibidores da il-18 para o tratamento e/ou prevenção de aterosclerose |
EP1297172B1 (en) | 2000-06-28 | 2005-11-09 | Glycofi, Inc. | Methods for producing modified glycoproteins |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
WO2002032374A2 (en) | 2000-10-18 | 2002-04-25 | Immunex Corporation | Methods for treating il-18 mediated disorders |
TWI313299B (en) | 2000-11-30 | 2009-08-11 | Medarex Inc | Transgenic transchromosomal rodents for making human antibodies |
ZA200305439B (en) | 2001-01-29 | 2004-07-15 | Applied Research Systems | Use of IL-18 inhibitors for the treatment and/or prevention of heat disease. |
US20040175756A1 (en) | 2001-04-26 | 2004-09-09 | Avidia Research Institute | Methods for using combinatorial libraries of monomer domains |
US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
US20050048512A1 (en) | 2001-04-26 | 2005-03-03 | Avidia Research Institute | Combinatorial libraries of monomer domains |
BR0213761A (pt) | 2001-10-25 | 2005-04-12 | Genentech Inc | Composições, preparação farmacêutica, artigo industrializado, método de tratamento de mamìferos, célula hospedeira, método para a produção de uma glicoproteìna e uso da composição |
WO2003057821A2 (en) | 2001-10-26 | 2003-07-17 | Centocor, Inc. | Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses |
CA2478855C (en) | 2002-03-22 | 2013-12-17 | Applied Research Systems Ars Holding N.V. | Use of il-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases |
FR2838444B1 (fr) | 2002-04-10 | 2016-01-01 | Neovacs | Nouveaux peptides et leur application en therapeutique |
JP4134166B2 (ja) | 2003-04-30 | 2008-08-13 | 独立行政法人科学技術振興機構 | ヒト抗ヒトインターロイキン−18抗体およびその断片、並びにそれらの利用方法 |
PL1622939T3 (pl) | 2003-05-13 | 2012-08-31 | Merck Serono Sa | Aktywne warianty białka wiążącego IL-18 i ich medyczne zastosowania |
DE10324447A1 (de) | 2003-05-28 | 2004-12-30 | Scil Proteins Gmbh | Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin |
SI1639011T1 (sl) | 2003-06-30 | 2009-04-30 | Domantis Ltd | Pegilirana protitelesa z enojno domeno (dAb) |
JP2005052021A (ja) | 2003-08-07 | 2005-03-03 | Yokohama City | インターロイキン−18変異体タンパク質 |
US20050075702A1 (en) | 2003-10-01 | 2005-04-07 | Medtronic, Inc. | Device and method for inhibiting release of pro-inflammatory mediator |
US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
US20050100965A1 (en) | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
WO2005075648A1 (en) | 2004-01-28 | 2005-08-18 | Gifu University | Interleukin-18 mutant proteins |
EP1744734A2 (en) | 2004-02-20 | 2007-01-24 | Novo Nordisk A/S | Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds |
WO2005097998A2 (en) | 2004-03-31 | 2005-10-20 | Regeneron Pharmaceuticals, Inc. | Il-18 specific polypeptides and therapeutic uses thereof |
US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
JP4673068B2 (ja) | 2005-01-19 | 2011-04-20 | 独立行政法人科学技術振興機構 | Th1型アレルギー疾患治療用組成物 |
US20070003981A1 (en) | 2005-06-29 | 2007-01-04 | Rules-Based Medicine, Inc. | Methods and kits for the diagnosis of acute coronary syndrome |
US20090215992A1 (en) | 2005-08-19 | 2009-08-27 | Chengbin Wu | Dual variable domain immunoglobulin and uses thereof |
NZ612578A (en) | 2005-08-19 | 2014-11-28 | Abbvie Inc | Dual variable domain immunoglobin and uses thereof |
PL2578685T3 (pl) | 2005-08-23 | 2020-01-31 | The Trustees Of The University Of Pennsylvania | Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania |
JP4728785B2 (ja) | 2005-11-30 | 2011-07-20 | 独立行政法人科学技術振興機構 | Il−18の生物活性を有する新規ポリペプチドの生産方法、および当該ポリペプチドの産生を阻害する物質のスクリーニング方法 |
ES2514495T3 (es) | 2006-05-25 | 2014-10-28 | Glaxo Group Limited | Anticuerpos humanizados modificados anti-interleucina-18 |
CA2697032C (en) | 2007-08-22 | 2021-09-14 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
CN102065892A (zh) | 2008-01-30 | 2011-05-18 | 雅培制药有限公司 | 用于使抗体片段结晶的组合物和方法 |
JP5723769B2 (ja) | 2008-06-03 | 2015-05-27 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリン及びその使用 |
BRPI0915448A2 (pt) | 2008-07-08 | 2015-11-10 | Abbott Lab | imunoglobulinas de domínio variável duplo para prostaglandina e2 e usos das mesmas |
US20110150871A1 (en) | 2008-08-18 | 2011-06-23 | Glaxo Group Limited | Treatment of an autoimmune disease using il-18 antagonists |
WO2010040736A2 (en) | 2008-10-07 | 2010-04-15 | Ablynx Nv | Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling |
TW201028433A (en) | 2008-10-20 | 2010-08-01 | Abbott Lab | Viral inactivation during purification of antibodies |
EP2346901A1 (en) | 2008-10-20 | 2011-07-27 | Abbott Laboratories | Antibodies that bind to il-18 and methods of purifying the same |
AP3995A (en) | 2008-12-23 | 2017-01-11 | Mtn Mobile Money Sa Pty Ltd | Method of and system for securely processing a transaction |
US20110008766A1 (en) | 2009-05-01 | 2011-01-13 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
MX2012009167A (es) | 2010-02-09 | 2012-08-23 | Glaxo Group Ltd | Tratamiento de un trastorno metabolico. |
BR112013015508B1 (pt) * | 2010-12-20 | 2022-04-05 | Medimmune Limited | Molécula de anticorpo para il-18 humana, domínio vh isolado e domínio vl isolado, composição, uso de uma molécula de anticorpo ou do domínio vh isolado e do domínio vl isolado, molécula de ácido nucleico isolada, célula hospedeira procariótica recombinante, método para produzir um anticorpo, e método in vitro para medir il-18 em uma amostra de um indivíduo |
JOP20200308A1 (ar) * | 2012-09-07 | 2017-06-16 | Novartis Ag | جزيئات إرتباط il-18 |
UY37758A (es) * | 2017-06-12 | 2019-01-31 | Novartis Ag | Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos |
-
2012
- 2012-09-07 JO JOP/2020/0308A patent/JOP20200308A1/ar unknown
-
2013
- 2013-09-04 US US14/017,561 patent/US9376489B2/en active Active
- 2013-09-05 ES ES13792452T patent/ES2804704T3/es active Active
- 2013-09-05 PL PL13792452T patent/PL2892923T3/pl unknown
- 2013-09-05 MA MA37892A patent/MA37892A1/fr unknown
- 2013-09-05 EP EP13792452.8A patent/EP2892923B1/en active Active
- 2013-09-05 EA EA201992614A patent/EA201992614A3/ru unknown
- 2013-09-05 MX MX2015002986A patent/MX2015002986A/es active IP Right Grant
- 2013-09-05 PT PT137924528T patent/PT2892923T/pt unknown
- 2013-09-05 RS RS20200663A patent/RS60394B1/sr unknown
- 2013-09-05 SG SG10201706623WA patent/SG10201706623WA/en unknown
- 2013-09-05 JO JOP/2013/0269A patent/JO3764B1/ar active
- 2013-09-05 JP JP2015530535A patent/JP6404817B2/ja active Active
- 2013-09-05 CN CN201811364662.1A patent/CN109517065B/zh active Active
- 2013-09-05 CA CA2883821A patent/CA2883821C/en active Active
- 2013-09-05 LT LTEP13792452.8T patent/LT2892923T/lt unknown
- 2013-09-05 WO PCT/IB2013/058317 patent/WO2014037899A2/en active Application Filing
- 2013-09-05 SI SI201331738T patent/SI2892923T1/sl unknown
- 2013-09-05 HU HUE13792452A patent/HUE050464T2/hu unknown
- 2013-09-05 BR BR122019028128-9A patent/BR122019028128B1/pt active IP Right Grant
- 2013-09-05 KR KR1020217001854A patent/KR102330653B1/ko active IP Right Grant
- 2013-09-05 DK DK13792452.8T patent/DK2892923T3/da active
- 2013-09-05 KR KR1020157008513A patent/KR102207672B1/ko active IP Right Grant
- 2013-09-05 AU AU2013311234A patent/AU2013311234A1/en not_active Abandoned
- 2013-09-05 EP EP20157418.3A patent/EP3725805A1/en active Pending
- 2013-09-05 MY MYPI2015700574A patent/MY174691A/en unknown
- 2013-09-05 AP AP2015008266A patent/AP2015008266A0/xx unknown
- 2013-09-05 SG SG11201501559VA patent/SG11201501559VA/en unknown
- 2013-09-05 PE PE2015000304A patent/PE20150649A1/es active IP Right Grant
- 2013-09-05 EA EA201590523A patent/EA034610B1/ru not_active IP Right Cessation
- 2013-09-05 BR BR112015004783-1A patent/BR112015004783B1/pt active IP Right Grant
- 2013-09-05 CN CN201380046530.3A patent/CN104640879B/zh active Active
- 2013-09-06 TW TW102132287A patent/TWI613217B/zh active
- 2013-09-06 AR ARP130103173A patent/AR092465A1/es unknown
- 2013-09-06 UY UY0001035016A patent/UY35016A/es not_active Application Discontinuation
- 2013-09-06 TW TW106136512A patent/TWI655208B/zh active
-
2015
- 2015-02-09 IL IL237161A patent/IL237161B/en active IP Right Grant
- 2015-02-10 ZA ZA2015/00954A patent/ZA201500954B/en unknown
- 2015-02-19 TN TNP2015000057A patent/TN2015000057A1/fr unknown
- 2015-03-04 PH PH12015500466A patent/PH12015500466A1/en unknown
- 2015-03-04 CL CL2015000532A patent/CL2015000532A1/es unknown
- 2015-03-06 GT GT201500054A patent/GT201500054A/es unknown
- 2015-03-06 MX MX2020007022A patent/MX2020007022A/es unknown
- 2015-03-06 CR CR20150121A patent/CR20150121A/es unknown
- 2015-03-06 CU CUP2015000022A patent/CU24249B1/es unknown
- 2015-03-06 CO CO15052159A patent/CO7400884A2/es unknown
- 2015-04-06 EC ECIEPI201513209A patent/ECSP15013209A/es unknown
- 2015-10-06 HK HK15109750.4A patent/HK1209136A1/xx unknown
-
2016
- 2016-03-18 AU AU2016201741A patent/AU2016201741B2/en active Active
- 2016-05-25 US US15/164,508 patent/US10081677B2/en active Active
-
2017
- 2017-12-06 AU AU2017272201A patent/AU2017272201B2/en active Active
-
2018
- 2018-08-24 US US16/111,659 patent/US11111293B2/en active Active
- 2018-09-12 JP JP2018170754A patent/JP2019037230A/ja active Pending
-
2019
- 2019-07-29 IL IL268336A patent/IL268336B/en unknown
- 2019-12-27 JP JP2019238049A patent/JP6944509B2/ja active Active
-
2020
- 2020-03-03 AU AU2020201556A patent/AU2020201556B2/en active Active
- 2020-06-05 HR HRP20200906TT patent/HRP20200906T1/hr unknown
- 2020-06-24 CY CY20201100582T patent/CY1123071T1/el unknown
-
2021
- 2021-07-27 US US17/386,429 patent/US20220098296A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123071T1 (el) | Μορια προσδεσης il-18 | |
CY1124698T1 (el) | Πρωτεϊνη δεσμευσης il-18 (il-18bp) σε φλεγμονωδεις νοσους | |
CY1124747T1 (el) | Ανθρωπινα αντισωματα σε pd-1 | |
CY1120398T1 (el) | Ανθρωποποιημενα αντισωματα που αναγνωριζουν αλφα-συνουκλεϊνη | |
MX2018004362A (es) | Anticuerpos anti-lag3 y sus usos. | |
CL2014003110A1 (es) | Anticuerpo anti-fcrn; secuencias que lo codifican; vector; célula huésped; proceso de producción; composición farmacéutica que lo comprende; uso para el tratamiento de enfermedad autoinmune; y ensayo para probar la capacidad de un anticuerpo para bloquear la actividad de fcrn humano. | |
EA201492137A1 (ru) | Антитела к cd33 и их применение в лечении рака | |
EA201492149A8 (ru) | St2-антигенсвязывающие белки | |
EA202091315A2 (ru) | Антитела человека, связывающиеся с g-белком rsv | |
CY1115349T1 (el) | Εξανθρωπισμενα αντι cxcr4 αντισωματα για τη θεραπεια καρκινου | |
MX2014014218A (es) | Moleculas de union il-6. | |
EA201591514A1 (ru) | Антитела к пан-хемокинам подсемейства elrcxc | |
MX2015005757A (es) | Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3. | |
EA201400447A1 (ru) | АНТИТЕЛА К CD1d | |
BR112014025560A2 (pt) | anticorpos anti-pdgf-c | |
EA201500503A1 (ru) | Анти-her3/her4 антигенсвязывающие белки, связывающиеся с бета-шпилькой her3 и бета-шпилькой her4 | |
MX366046B (es) | Moléculas de unión que se adhieren al factor de complemento c2 humano y usos de los mismos. | |
BR112013023513A2 (pt) | anticorpos que ligam tgf-alfa e epiregulina | |
NZ716687A (en) | Il-18 binding molecules | |
TH167242A (th) | โมเลกุลการยึดเกาะ il-18 | |
TH167242B (th) | โมเลกุลการยึดเกาะ il-18 | |
NZ768582A (en) | Antibodies and uses thereof to detect folate receptor 1 | |
TH159056A (th) | แอนติบอดีต่อ hla-b*27และการใช้มัน |